HD-OPM Archive
Hashtags

#statinreverse

39 posts

Intensive statin reversed atherosclerosis on IVUS in a 2004 Cleveland Clinic-led trial

Dec 23, 2023 · Louis Nervegna ♥ 20 · 💬 40 ↩ 12 Plaque, CAC & CT angiography

Louis shares a Cleveland Clinic video to counter the claim that statins do not reverse plaque. The 2004 trial used intravascular ultrasound (IVUS), which he calls the gold standard for plaque imaging, and showed regression with high-dose statin driving LDL-C down to about 60 mg/dL. He stresses LDL must be very low to achieve regression.

Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18%

Sep 13, 2025 · Louis Nervegna ♥ 19 · 💬 23 ↩ 21 Plaque, CAC & CT angiography

Summary of the Japan-ACS trial, in which over 300 acute coronary syndrome patients were randomized to pitavastatin or atorvastatin and imaged with IVUS. Both statins produced similar, substantial regression of non-culprit plaque volume as LDL fell into the 80s mg/dL, which is one reason statins remain standard care after ACS.

Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years

Oct 06, 2025 · Louis Nervegna ♥ 29 · 💬 14 Statins

Responding to influencers who say plaque cannot be reversed with statins, Louis cites a case report in which a patient taking low-dose atorvastatin went from a severe to a mild LAD narrowing, documented on CT angiography. It is a single case, but illustrates that statin-associated plaque regression can occur.

Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS

Jan 18, 2025 · Louis Nervegna ♥ 10 · 💬 29 ↩ 9 Plaque, CAC & CT angiography

Louis lists human trials in which statins reversed or halted atheroma growth measured as percent atheroma volume (PAV). High-dose atorvastatin and rosuvastatin regressed PAV in SATURN and ASTEROID, while REVERSAL showed halted progression versus pravastatin. COSMOS added canakinumab to rosuvastatin, and PROSPECT and JAPAN-ACS showed lower progression on statins.

Six RCTs show statins reverse total plaque volume by 5% to 17%

Aug 25, 2026 · Louis Nervegna ♥ 27 · 💬 9 ↩ 1 Plaque, CAC & CT angiography

Louis lists six randomized trials showing reversal of total atheroma volume with statins: COSMOS ~5%, SATURN ~5.5%, ASTEROID ~6.5%, IBIS-4 ~7.5%, STABLE ~8%, JAPAN-ACS ~17%. Reversals were measured by CT angiography or IVUS and came from soft rather than calcified plaque. A shared chart relates LDL to TAV change across statin, PCSK9 and ezetimibe trials.

YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks

Aug 15, 2026 · Louis Nervegna ♥ 16 · 💬 19 Plaque, CAC & CT angiography

The YELLOW study found that short-term intensive lipid lowering with rosuvastatin reduced lipid-core burden (yellow plaque) in coronary lesions in as little as 7-8 weeks, stabilizing vulnerable plaque rather than shrinking blockages. YELLOW III added the PCSK9 inhibitor evolocumab to statins with greater improvement in plaque composition. Generic rosuvastatin costs under $10/month.

FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months

Oct 31, 2026 · Louis Nervegna ♥ 25 · 💬 11 Plaque, CAC & CT angiography

Louis highlights the randomized FLOWPROMOTE trial in 104 statin-naive patients with coronary artery disease, scanned by CT angiography at baseline, 9 and 18 months. Rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL-C to 42.5 mg/dL versus 69.5 mg/dL with atorvastatin 40 mg and reduced total plaque volume by about 21%. The shared write-up frames this as evidence that coronary atherosclerosis can be reversed with intensive lipid lowering.

About 95% of acute-thrombosis heart attacks involve soft plaque, not calcified plaque

Oct 03, 2026 · Louis Nervegna ♥ 9 · 💬 9 Plaque, CAC & CT angiography

The post says about 64% of heart attacks from acute thrombosis come from rupture of soft lipid-rich plaque and about 25% from erosion of soft plaque, while only about 5% involve calcified nodules. Because statins and other lipid-lowering drugs stabilize and reverse soft plaque, the poster argues they address the plaque type most responsible for heart attacks.

FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43

Oct 31, 2026 · Louis Nervegna ♥ 14 · 💬 4 Plaque, CAC & CT angiography

Louis adds FLOWPROMOTE to the pile of randomized trials showing statins reverse soft and total plaque. In 104 statin-naive stable CAD patients on CT angiography, LDL around 70 mg/dL gave a 13.6% total plaque reduction and around 43 mg/dL gave 21.1%, with 90% of the lower-LDL group showing regression. The linear LDL-to-regression relationship supports LDL being causal in atherosclerosis.

FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression

Nov 07, 2026 · Louis Nervegna ♥ 13 · 💬 5 Plaque, CAC & CT angiography

Louis shares an explainer of FLOWPROMOTE, a 2026 JAMA Cardiology randomized trial in 104 Danish adults with stable coronary disease and no prior statin. Participants received atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg for 18 months with serial coronary CT angiography. It also explains how LDL drives plaque and why combining drugs lowers LDL further.

Case: carotid plaque regression with salmon, niacin and low-dose rosuvastatin

Dec 23, 2023 · Louis Nervegna ♥ 13 · 💬 3 Plaque, CAC & CT angiography

Louis shares a video by Dr. Ford Brewer describing his own plaque reversal. He ate salmon daily, added niacin and low-dose rosuvastatin and switched from an ARB to an ACE inhibitor, with a major decrease in carotid plaque volume and CIMT arterial age falling from 72 to 52. It is a single self-reported case in a video from a clinic that also sells services and supplements.

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Oct 31, 2026 · Louis Nervegna ♥ 12 ↩ 1 Plaque, CAC & CT angiography

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.

A rising calcium score on a statin does not mean it failed, per FLOWPROMOTE details

Nov 08, 2026 · Louis Nervegna ♥ 1 Plaque, CAC & CT angiography

Louis shares a cardiologist's explanation that a higher calcium score on a statin neither proves failure nor success, since plaque picks up calcium as it hardens and denser calcium counts extra. It summarizes FLOWPROMOTE: atorvastatin 40 mg vs rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL more and shrank total plaque more in 18 months while calcified plaque grew in both groups. These were secondary results of a small trial on CT, not event outcomes.